Hong Kong stocks surge | CRO concept stocks continue to rise, innovative drug policies are expected to continue to strengthen, Citigroup said the CXO sector is attracting market attention ahead of the earnings season

According to the Securities Times APP, CRO concept stocks continue to rise. As of the time of publication, Celltrion RE (06821.HK) rose by 12.06% to 108.7 Hong Kong dollars; Conba Pharmaceutical (03759.HK) rose by 6.66% to 20.65 Hong Kong dollars; Junshi Biosciences (06127.HK) rose by 6.56% to 22.75 Hong Kong dollars; and WuXi Biologics (02269) rose by 3.65% to 29.8 Hong Kong dollars.